KIT and prostate carcinoma: Blockade of Kv and/or KCa channels is demonstrated to inhibit proliferation in glial cells, lymphocytes, endothelium, breast and prostate cancer cells [23], and in bone marrow-derived MSCs from mouse [18], rat [17] and human [24], mouse cardiac c-kit+ progenitor cells [25], rat vascular smooth muscle cells [20, 26], and also in rat and human cardiac fibroblasts [15, 27].